CoChat

Double-Blind Study of Dextroamphetamine Versus Caffeine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder

Koran, Lorrin M., Aboujaoude, Elias, Gamel, Nona N. · 2009 · The Journal of Clinical Psychiatry

The DOI matches its Crossref record.

Abstract

INTRODUCTION: Two small, double-blind, placebo-controlled, single-dose, crossover studies found dextroamphetamine (d-amphetamine) 30 mg clearly superior to placebo in relieving symptoms of obsessive-compulsive disorder (OCD). We conducted a 5-week, double-blind, caffeine-controlled study to test the hypothesis that d-amphetamine, added after an adequate selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) trial, would be more effective than caffeine in reducing residual OCD symptoms of moderate or greater severity. METHOD: Between August 2006 and February 2008, we enrolled adults with DSM-IV OCD and a Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score of >or= 20 after >or= 12 weeks of adequate treatment with an SSRI or SNRI. Subjects were randomly assigned to double-blind d-amphetamine 30 mg/d or caffeine 300 mg/d added to their SSRI/SNRI and other medications. Responders (first week mean Y-BOCS score decrease of >or= 20%) entered the study's 4-week double-blind extension phase. RESULTS: We enrolled 24 subjects, 11 women and 13 men, with a mean (SD) age of 40 (13.2) years and mean baseline Y-BOCS scores of 26.5 (4.1) for the d-amphetamine group (n = 12) and 29.1 (4.0) for the caffeine group (n = 12). At the end of week 1, 6 of 12 d-amphetamine subjects (50%) and 7 of 12 caffeine subjects (58%) were responders. At week 5, the responders' mean Y-BOCS score decreases were, for the d-amphetamine group (last observation carried forward), 48% (range, 20%-80%); and, for the caffeine group, 55% (range, 27%-89%). Obsessive-compulsive disorder and depression improvement were independent. The double-blind remained intact. No subject discontinued the study due to side effects. CONCLUSIONS: Larger, double-blind, placebo-controlled trials of both d-amphetamine and caffeine augmentation are needed in OCD subjects inadequately responsive to adequate doses of an SSRI or SNRI. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00363298.

Overview

Integrity signals

Registry

Crossref · 10.4088/jcp.08m04605

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cited by

Metadata

Authors
Koran, L. M., Aboujaoude, E., & Gamel, N. N.
Affiliations
Stanford University (US)
Venue
The Journal of Clinical Psychiatry
Published
2009-06-30
Volume
70
Issue
11
Pages
1530-1535
ISSN
0160-6689 (ISSN-L)
OpenAlex
W2081132633
Cited by
79
References
0
Citations by year
2026: 4 · 2025: 5 · 2024: 3 · 2023: 3 · 2022: 3 · 2021: 5 · 2020: 6 · 2019: 3 · 2018: 3 · 2017: 3 · 2016: 3 · 2015: 7 · 2014: 8 · 2013: 5 · 2012: 3
FWCI
6.37
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
Keywords
obsessive-compulsive disorder, d-amphetamine, treatment-resistant OCD, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, Yale-Brown Obsessive Compulsive Scale, adverse effects, treatment discontinuation
MeSH terms
Adult, Caffeine, Dextroamphetamine, Double-Blind Method, Drug Administration Schedule, Drug Resistance, Drug Therapy, Combination, Female, Humans, Longitudinal Studies, Male, Middle Aged, Obsessive-Compulsive Disorder, Psychiatric Status Rating Scales, Neurotransmitter Uptake Inhibitors, Treatment Outcome, Selective Serotonin Reuptake Inhibitors, Diagnostic and Statistical Manual of Mental Disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.